Compare Firy Inc. (FIRY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Mesoblast Limited — how do they compare? Firy Inc. trades at $8.41 (market cap $125.48M), while Mesoblast Limited trades at $19.04 (market cap $2.31B). The key difference: Mesoblast Limited is far larger — about 18.4× Firy Inc.'s market cap, and Mesoblast Limited is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| FIRY | MESO | |
|---|---|---|
Market Cap | $125.48M | $2.31B |
Sector | Consumer Cyclical | Technology |
52-Week High | $12.45 | $20.96 |
52-Week Low | $2.28 | $11.35 |
Enterprise Value | $69.16M | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $8.04, down 4.74% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. The company recently rebranded and reported Q1 2026 results showing revenue growth to $104.5M but persistent losses with a net margin of -57.48%. Cash flow remains negative at -$86.41M for 2025, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term support at $8, fundamental challenges include deep losses and negative cash flow. Analyst sentiment is mixed with 60% hold ratings. Key risks are profitability timeline and competitive pressure, but rebranding and legal victories may support long-term turnaround if execution improves.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
